Pres. Trump announces deal with AstraZeneca to lower U.S. drug prices

Government Policy & Drug Pricing - Melissa Astroenetica becomes the second drug maker to join President Trump's most favored nation drug price program [1] - The administration aims to align 95% of US drug prices with European levels [3] - Fizer reached an agreement to provide drugs at lower prices for Medicaid and invest $70 billion in the US, in exchange for tariff exemption for three years [2] - CMS administrator Dr Oz is central to these negotiations [1][2] - The next round of IRA price negotiation prices will be available next month [5] Company Investment & Operations - Melissa Astroenetica is breaking ground on a $45 billion plant in Virginia [1] - Fizer is making a $70 billion investment in the US, including manufacturing [2] Future Outlook & Negotiation Strategies - The administration is reaching out to many firms regarding drug pricing [3] - Medicare innovation pilots are being considered to address drug prices [5] - Dr Ash indicates that Medicare is also being considered [4] - The team is negotiating aggressively on drug prices [5]